Anavex Compound to be Tested in Biogen Neurological Protection Model
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Biogen Agreement Further Validates Anavex Life Sciences (AVXL) AV2-73 - FBR
September 28, 2016 10:39 AM EDTFBR Capital analyst Christopher James weighed in on Anavex Life Sciences (NASDAQ: AVXL) after the company announced that it has signed a material transfer agreement with Biogen under which Biogen will test AV2-73 in a validated preclinical CNS assay. As a... More
Anavex Life Sciences (AVXL) Surges Higher; Stock Up 47%
September 28, 2016 10:12 AM EDTAnavex Life Sciences (NASDAQ: AVXL) surges to highs following this morning's testing deal with Biogen (NASDAQ: BIIB). Shares are up 46.8% on volume that is 37x normal.
... More